{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:15:48Z","timestamp":1786994148481,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.metabol.2014.04.008","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T19:39:50Z","timestamp":1398281990000},"page":"957-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-4760","authenticated-orcid":false,"given":"Giuseppe","family":"Derosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.metabol.2014.04.008_bb0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/dia.2011.0204","article-title":"Dipeptidyl peptidase-4 inhibitors: 3years of experience","volume":"14","author":"Derosa","year":"2012","journal-title":"Diabetes Technol Ther"},{"issue":"17","key":"10.1016\/j.metabol.2014.04.008_bb0010","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1517\/14656566.2012.730519","article-title":"A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and \u03b2-cell function","volume":"13","author":"Derosa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.008_bb0015","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/dme.12158","article-title":"A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycaemic control and \u03b2-cell function: the triple oral therapy","volume":"30","author":"Derosa","year":"2013","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.008_bb0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.metabol.2009.10.007","article-title":"Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients","volume":"59","author":"Derosa","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.04.008_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2013.04.005","article-title":"Evaluation of the positive effects on insulin-resistance and \u03b2-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients","volume":"73","author":"Derosa","year":"2013","journal-title":"Pharmacol Res"},{"issue":"18","key":"10.1016\/j.metabol.2014.04.008_bb0030","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1517\/14656566.2012.734499","article-title":"Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study","volume":"13","author":"Derosa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.008_bb0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/dia.2011.0278","article-title":"Vildagliptin added to metformin on \u03b2-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients","volume":"14","author":"Derosa","year":"2012","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"10.1016\/j.metabol.2014.04.008_bb0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1055\/s-0030-1255036","article-title":"Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients","volume":"42","author":"Derosa","year":"2010","journal-title":"Horm Metab Res"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.008_bb0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003088-200746070-00003","article-title":"Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus","volume":"46","author":"He","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.metabol.2014.04.008_bb0050","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidylpeptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.04.008_bb0055","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2014.04.008_bb0060","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1210\/jc.2006-1882","article-title":"The dipeptidylpeptidase-4 inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients","volume":"92","author":"Balas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.008_bb0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1210\/en.2008-1137","article-title":"Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice","volume":"150","author":"Duez","year":"2009","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.metabol.2014.04.008_bb0070","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1210\/jc.2012-1205","article-title":"Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes","volume":"97","author":"Muscelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.04.008_bb0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1210\/jc.2007-1369","article-title":"Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes","volume":"93","author":"Azuma","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.04.008_bb0080","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1210\/jc.2008-1400","article-title":"Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients","volume":"94","author":"Boschmann","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.008_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11883-001-0036-5","article-title":"Recent findings in the study of postprandial lipemia","volume":"3","author":"Parks","year":"2001","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.008_bb0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jacl.2012.02.010","article-title":"Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp an oral fat load","volume":"6","author":"Derosa","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.metabol.2014.04.008_bb0095","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ejlt.201000504","article-title":"Effects of n-3 PUFAs on insulin resistance after an oral fat load","volume":"113","author":"Derosa","year":"2011","journal-title":"Eur J Lipid Sci Technol"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.008_bb0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0031-1275704","article-title":"Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load","volume":"43","author":"Derosa","year":"2011","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.008_bb0105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdiacomp.2011.01.003","article-title":"Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study","volume":"25","author":"Derosa","year":"2011","journal-title":"J Diabetes Complications"},{"issue":"1\u20133","key":"10.1016\/j.metabol.2014.04.008_bb0110","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejphar.2010.11.015","article-title":"Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load","volume":"651","author":"Derosa","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.008_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00380-008-1109-y","article-title":"Oral fat load effects on inflammation and endothelial stress markers in healthy subjects","volume":"24","author":"Derosa","year":"2009","journal-title":"Heart Vessels"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.008_bb0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/hr.2009.212","article-title":"Candesartan effect on inflammation in hypertension","volume":"33","author":"Derosa","year":"2010","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.008_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mvr.2010.03.012","article-title":"Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects","volume":"80","author":"Derosa","year":"2010","journal-title":"Microvasc Res"},{"issue":"1","key":"10.1016\/j.metabol.2014.04.008_bb0130","first-page":"88","volume":"28","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2014.04.008_bb0135","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.ATV.0000238352.25222.5e","article-title":"Summary of American Heart Association diet and lifestyle recommendations revision 2006","volume":"26","author":"Lichtenstein","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2014.04.008_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1126\/science.635569","article-title":"The glycosylation of haemoglobin. Relevance to diabetes mellitus","volume":"200","author":"Bunn","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.metabol.2014.04.008_bb0145","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","article-title":"A desktop guide to type 2 diabetes mellitus","volume":"16","author":"European Diabetes Policy Group","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2014.04.008_bb0150","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF01225569","article-title":"Determination of total serum insulin (IRI) in insulin-treated diabetic patients","volume":"8","author":"Heding","year":"1972","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2014.04.008_bb0155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2014.04.008_bb0160","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2014.04.008_bb0165","first-page":"121","article-title":"Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II)","volume":"15","author":"Klose","year":"1978","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.metabol.2014.04.008_bb0170","series-title":"Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis","first-page":"18","author":"Wahlefeld","year":"1974"},{"key":"10.1016\/j.metabol.2014.04.008_bb0175","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2014.04.008_bb0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.008_bb0185","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/clinchem\/44.7.1514","article-title":"First direct assay for intact human proinsulin","volume":"44","author":"Houssa","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2014.04.008_bb0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/bj2070381","article-title":"Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33\u201369) of glicentin","volume":"207","author":"Holst","year":"1982","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.metabol.2014.04.008_bb0195","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1210\/jc.2002-021604","article-title":"Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans","volume":"88","author":"Yannakoulia","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2014.04.008_bb0200","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1210\/jc.2006-1249","article-title":"Retinol binding protein-4 levels and clinical features of type 2 diabetes patients","volume":"92","author":"Takebayashi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.04.008_bb0205","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1073\/pnas.0504703102","article-title":"Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity","volume":"102","author":"Hida","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2014.04.008_bb0210","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1210\/jc.2007-1304","article-title":"Molecular characteristics of serum visfatin and differential detection by immunoassays","volume":"92","author":"Korner","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2014.04.008_bb0215","first-page":"214","article-title":"Glucose clamp technique, a method for quantifying insulin secretion and resistance","volume":"237","author":"De Fronzo","year":"1979","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.008_bb0220","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM198708063170605","article-title":"Insulin resistance in essential hypertension","volume":"317","author":"Ferrannini","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2014.04.008_bb0225","series-title":"Statistical principles in experimental design","author":"Winer","year":"1971"},{"issue":"5","key":"10.1016\/j.metabol.2014.04.008_bb0230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4093\/dmj.2011.35.5.529","article-title":"Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients","volume":"35","author":"Jeon","year":"2011","journal-title":"Diabetes Metab J"},{"issue":"5","key":"10.1016\/j.metabol.2014.04.008_bb0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc12-1365","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency","volume":"36","author":"Arjona Ferreira","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.metabol.2014.04.008_bb0240","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.12146","article-title":"Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring","volume":"15","author":"He","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.metabol.2014.04.008_bb0245","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2362.32.s3.5.x","article-title":"The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes","volume":"32","author":"Bergman","year":"2002","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2014.04.008_bb0250","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1463-1326.2008.01021.x","article-title":"Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-na\u00efve patients with type 2 diabetes mellitus","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.04.008_bb0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/fcp.12001","article-title":"Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation","volume":"28","author":"Derosa","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.metabol.2014.04.008_bb0260","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.metabol.2014.04.008_bb0265","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":"Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes","volume":"90","author":"Mari","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514001164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514001164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:04:30Z","timestamp":1758427470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514001164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0026049514001164"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.04.008","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}